-
Media ReleaseMedia Statement: FortiHFy Global Clinical Program for Entresto®
-
Media ReleaseNovartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes
-
Media ReleaseLargest global psoriasis survey shows 85% of U.S. respondents faced social stigma like discrimination and humiliation because of their skin
-
Media ReleaseTimely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology
-
Media ReleaseNovartis data show Gilenya® had significantly greater patient retention compared to iDMTs in relapsing-remitting MS
-
Media ReleaseNovartis BAF312 reduced the risk of disability progression in pivotal phase III study in secondary progressive MS patients
-
Media ReleaseNovartis data finds relapsing MS patients on Gilenya® had greater treatment retention and satisfaction rates vs. injectable DMTs
-
Media ReleaseNovartis announces FDA approval of Xolair® (omalizumab) for pediatric allergic asthma
-
Media ReleaseNovartis late-breaking data show Cosentyx® continues to deliver high skin clearance for majority of psoriasis patients at four years
-
Media ReleaseNovartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions
-
Media ReleaseImportant new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients
-
Media ReleaseNew analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths